C. R. Bard, Inc., now branded simply as Bard, headquartered in Murray Hill, New Jersey, USA, was a developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties before its acquisition by BD. In April 2017, the company has announced that it will be acquired by Becton Dickinson. C. R. Bard, Inc.’s has been at the forefront of developing innovative medical devices in the fields of urology, oncology, vascular and surgical specialties. Explore how we are enhancing lives, improving outcomes, and exceeding the expectations of clinicians and patients all over the world. For more than a century, C. R. Bard, Inc. has been at the forefront of developing innovative medical devices that solve the challenges of healthcare professionals and patients. Watch our video to learn how Bard is pursuing technological innovations that offer superior clinical benefits while helping to reduce overall health care costs. 關於 C. R. Bard, Inc. 我們為患者與醫療保健人員提供健康、預防、早期診斷、治療以及後期護理管理方面的服務。事實上，縱觀我們的歷史， Bard 引領行業獲得了突破性的裝置和治療方法方面的發展，並且持續不斷地尋求新的卓越與品質標準。 新浪财经-美股频道为您提供巴德集团(BCR)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与巴德集团(BCR)股票相关的信息与服务 巴德集团 NYSE:BCR C. R. Bard, Inc. (Ne 添加 C R Bard Inc (NYSE:BCR) announced its earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. Inside Bard C R Inc's 10-K Annual Report: Legal - Other Highlight These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings and other litigation
28 Dec 2017 C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient
30 Nov 2019 C R Bard : BD Completes Bard Acquisition, Creating New Global Health Care Leader. 12/2017 12/2017. C R BARD INC : Ex-dividend day for 24 Apr 2017 C.R. Bard (NYSE:BCR) stock soared 19.5% higher on Monday after medical supply giant Becton, Dickinson (NYSE:BDX) announced it's 25 May 2020 Real-time trade and investing ideas on CR Bard Inc. BCR from the largest community of traders and investors. We apologize for any inconvenience. Refresh or try again later. Trade with Jim Cramer 14 Days Free. Join the Action Alerts PLUS Community today!
C. R. Bard was acquired by Becton Dickinson for $24B on Apr 23, 2017 . This deal was done in Cash & Stock . Transaction Name.
Inside Bard C R Inc's 10-K Annual Report: Legal - Other Highlight These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings and other litigation About C. R. Bard, Inc. For patients and healthcare professionals in wellness and prevention, early diagnosis, treatment, and post-care management. In fact, throughout our history, Bard has lead the industry in groundbreaking devices and therapies that continuously seek to set the new standard for excellence and quality. C. R. Bard, Inc. has pioneered the development and manufacture of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. You are now leaving the Bard Website. Any links or references to other Internet sites (hyperlinks) are provided by Bard merely as a convenience to users of this About C. R. Bard, Inc. For patients and healthcare professionals in wellness and prevention, early diagnosis, treatment, and post-care management. In fact, throughout our history, Bard has lead the industry in groundbreaking devices and therapies that continuously seek to set the new standard for excellence and quality. C. R. Bard, Inc. ist ein führender internationaler Entwickler, Hersteller und Anbieter von Medizinprodukten in den Bereichen Gefäßerkrankungen, Urologie, Onkologie und chirurgische Spezialprodukte. Lernen Sie uns kennen.
25 May 2020 Real-time trade and investing ideas on CR Bard Inc. BCR from the largest community of traders and investors.
24 Apr 2017 BD said it would pay a combination of cash and stock worth $317 per share of Bard stock. C.R. Bard shares rose nearly 20% to $303.04 in late
C. R. Bard, Inc. has pioneered the development and manufacture of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. You are now leaving the Bard Website. Any links or references to other Internet sites (hyperlinks) are provided by Bard merely as a convenience to users of this
23 Apr 2017 Becton, Dickinson and Company (NYSE: BDX) and C. R. Bard, Inc. will acquire Bard for $317.00 per Bard common share in cash and stock, In 1923, C.R. Bard incorporated to distribute catheters and other urology-related medical devices – largely from French suppliers. For the next 40 years, Bard's 2019年12月4日 股票代码：BDXA 赛默飞世尔科技(Thermo Fisher Scientific Inc., TMO)周五表示， 已同意 N) 将以240亿美元现金加股票收购C R Bard (BCR.